The culture of collaboration in the Pacific Northwest, the impact of AI on biopharma, and the shape of new business models driven by AI were all topics at a panel discussion Wednesday in Seattle at the 2024 Life Science Innovation Northwest meeting.
In September, Microsoft released an open-source model to generate proteins, and other big tech companies are betting on the field. One major aim is to not only discover new therapeutic proteins but to shorten their clinical development through “quality by design,” said Stuart. Researchers can now assess proteins for traits such as ease of manufacture or unwanted cross-reactivity to other molecules, she said.
The use of AI in biopharma also goes beyond protein design. Bristol Myers Squibb, which has more than 1,500 employees in the Seattle area, uses machine learning to mine internal data to match patients for clinical trials, said Danielle Greenawalt, scientific executive director of translational informatics and predictive sciences at BMS.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
